Semaglutide News and Research

Latest Semaglutide News and Research

Beta-Pro donates human pancreatic islet cells to diabetes researcher

The cellular services company Beta-Pro LLC, announced today that it donated more than 300,000 human pancreatic islet cells to nationally renowned diabetes researcher Raghavendra G. Mirmira, M.D., Ph.D., the Eli Lilly & Co. Professor of Pediatric Diabetes, Indiana University School of Medicine, Herman B.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Emisphere Technologies, Inc. today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects.

18 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

5 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Redpoint Bio issued patent that covers high-throughput screening technology

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced the issuance of Patent No. 7,749,730 B2 by the U.S. Patent and Trademark Office entitled "High Throughput Screening Assay for the TRPm5 Ion Channel."

28 Jul 2010

QPS acquires Xendo Drug Development

QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands. XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

26 Jul 2010

Five new large pharma clients place initial studies with LAB Research

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that five new large pharma clients have placed initial studies with the Company following the successful pre-qualification of its sites. These new clients are expected to represent at least 5-10% of the Company's revenues by 2011.

21 Jul 2010

Absorption Systems' GLP facility receives full accreditation from AAALAC

Absorption Systems, a leader in testing drugs for ADMET, announced today that its GLP facility in San Diego, Calif., for preclinical testing of drugs, biologics and medical devices received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International.

15 Jul 2010

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

Philippine FDA's LSD attains ISO/IEC 17025:2005 accreditation for testing and calibration laboratories

In an effort that will contribute to raising the quality of medicines in the Philippines and surrounding regions, the Laboratory Services Division (LSD) of the Philippine Food and Drug Administration (FDA) has attained the internationally recognized accreditation for testing and calibration laboratories, International Organization for Standardization/ International Electrotechnical Commission (ISO/IEC) 17025:2005.

13 Jul 2010

Semaglutide News and Research

Latest Semaglutide News and Research

Beta-Pro donates human pancreatic islet cells to diabetes researcher

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Lixisenatide experimental diabetes drug shows potential in trial

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Redpoint Bio issued patent that covers high-throughput screening technology

QPS acquires Xendo Drug Development

Five new large pharma clients place initial studies with LAB Research

Absorption Systems' GLP facility receives full accreditation from AAALAC

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

Philippine FDA's LSD attains ISO/IEC 17025:2005 accreditation for testing and calibration laboratories

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in